FIG 3
Comparison of the behavior of E403X and E403K mutant TRα receptors. (A) Two-hybrid assay to investigate the ability of ligand (T3) to dissociate NCoR and recruit TRAP220. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ***, P < 0.0001 for comparisons of WT versus TRα mutants. (B) Analysis of KLF9 expression in patient-derived primary cells containing WT TRα or the E403X and E403K mutant TRα receptors. *, P < 0.05; **, P < 0.01 for comparisons of E403X versus E403K mutant TRα. (C) Electrophoretic mobility shift assays with WT, E403X or E403K mutant TRα, and RXR, with a canonical thyroid hormone response element (TRE) (DR + 4) or a known TRE in the human KLF9 promoter, in the presence of 1 μM T3 or 1 μM ES08. |